Damora Therapeutics, Inc. Common Stock’s (DMRA) “Outperform” Rating Reiterated at Wedbush

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research report issued on Friday,Benzinga reports. They currently have a $35.00 target price on the stock. Wedbush’s price target would suggest a potential upside of 65.96% from the company’s previous close.

A number of other research analysts have also weighed in on the company. Royal Bank Of Canada initiated coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They set an “outperform” rating and a $40.00 price objective for the company. TD Cowen assumed coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday. They issued a “buy” rating on the stock. UBS Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. They set a “buy” rating and a $45.00 price target for the company. HC Wainwright began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Thursday. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Evercore started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, March 25th. They set an “outperform” rating and a $46.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Damora Therapeutics, Inc. Common Stock has an average rating of “Moderate Buy” and a consensus target price of $42.43.

Damora Therapeutics, Inc. Common Stock Price Performance

NASDAQ DMRA traded down $0.27 during trading hours on Friday, reaching $21.09. 32,439 shares of the company’s stock traded hands, compared to its average volume of 272,964. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33. The firm has a 50-day simple moving average of $24.59 and a 200 day simple moving average of $25.37. The firm has a market cap of $1.30 billion, a PE ratio of -3.78 and a beta of 1.46.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.23). Sell-side analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.13 EPS for the current fiscal year.

Institutional Trading of Damora Therapeutics, Inc. Common Stock

Institutional investors and hedge funds have recently modified their holdings of the business. Ikarian Capital LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the fourth quarter valued at $6,574,000. Jain Global LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,774,000. Remedium Capital Partners LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,772,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,204,000. Finally, Connective Capital Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $100,000. Institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.